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Summary b2-adrenoreceptor agonists are able to modulate various aspects of airway
cell functions involved in the inflammatory and repair processes characterizing a
variety of respiratory disorders. Human bronchial epithelial cells (HBECs), which can
act as immune effector cells and express b2-adrenoreceptors, were used to test the
effects of different concentrations (0.1–100.0 nM) of salmeterol (Salm) on adhesion
molecule expression and chemokine/cytokine release. HBECs, freshly isolated from
resected bronchi at the time of surgery in ex-smokers with lung cancer, constitutively
expressed over 3 times more ICAM-1 than VCAM-1 (Po0.05) and secreted greater
amounts of IL-8 than of GM-CSF or RANTES (Po0.001). Stimulation of HBECs with IL-4,
TNF-a or IL-4 plus TNF-a-upregulated ICAM-1 expression (Po0.05) and increased GM-
CSF and IL-8 secretion (Po0.05). Similarly, VCAM-1 expression was significantly
increased by IL-4 plus TNF-a, while RANTES release was significantly enhanced by IL-4
or by IL-4 plus TNF-a (Po0.05), but not by TNF-a alone (P40.05). Dose-response
curves showed that Salm, at concentration 41.0 nM, was effective in inhibiting
adhesion molecule expression and cytokine release by HBECs (Po0.05). At a Salm
concentration of 10 nM the degree of inhibition observed was similar for ICAM-1 and
VCAM-1 expression (37.279.3% and 32.979.6%, respectively; P40.05), but higher
for RANTES (88.474.4%), as compared to IL-8 (21.877.0%) or GM-CSF (30.176.6%;
Po0.05, each comparison). Thus, adhesion molecules and cytokines may be
expressed/released at very different levels by unstimulated or stimulated HBECs
and those activities appear to be modulated by Salm.
r 2003 Elsevier Ltd. All rights reserved.
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Introduction
Besides being a physical and functional barrier to
external agents, bronchial epithelial cells appear
to be involved in the pathogenesis of the inflam-
matory and repair processes that characterize a
variety of respiratory disorders.1 Indeed, airway
epithelial cells express adhesion molecules in-
volved in cell–cell and cell–extracellular matrix
interaction and are source of mediators capable of
sustaining inflammation and facilitating repair and
remodelling processes that follow injury.1,2 These
considerations have lead to the concept that these
cells should be considered a major target for
therapeutic intervention.1–3
b2-adrenoreceptor activity is a key part of the
physiological and pharmacological response in
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subjects with chronic obstructive lung diseases.4
Indeed, bronchial smooth muscle relaxation results
directly from b2-adrenoreceptor stimulation.
5 How-
ever, since these receptors have been identified on
many cells in the lung, including bronchial epithe-
lial cells, it should be expected that b2-adrenor-
eceptor agonists might mediate a variety of other
functions through the stimulation of b2-adrenergic
receptors expressed on other cell types.6 In this
context, these drugs may inhibit plasma exudation
acting on postcapillary venule endothelial cells and
effectively downregulate the release of broncho-
constrictor substances from mast cells and of
proinflammatory mediators from eosinophils, neu-
trophils, macrophages, and T-cells.7–10 By contrast,
the effect of b2-agonists on airway epithelial cell
functions is uncertain and sometimes contradic-
tory.6 While it is established that at least in vitro
b2-adrenoreceptors may increase ciliary beat fre-
quency,1,11,12 cell proliferation,13 heat shock pro-
teins14 and monocyte adhesion to airway
epithelium via cAMP-mediated changes in epithelial
cells,15 less clear is their activity on bronchial
epithelial cell pro-inflammatory functions. Indeed,
while with short-acting b2-adrenoreceptor agonists
inhibition of adhesion molecule expression16 and no
effect or downregulation of IL-8 and GM-CSF
release have been reported,17,18 inhibition of GM-
CSF associated with increase production of IL-8
were observed when exposing human airway
epithelial cells to the long-acting b2-adrenorecep-
tor agonist formoterol.19 Discrepancies in the
results may be related to differences in the source
of cells, experimental conditions cell types, on the
cell functions evaluated and on the characteristics
of the compound tested.4–6,20–22
With this background a study was designed to
test in vitro the activity of another long-acting b2-
adrenoreceptor agonist widely used in the treat-
ment of patients with asthma and other chronic
obstructive lung diseases, salmeterol, on freshly
isolated human bronchial epithelial cells. The cells
were stimulated with IL-4 and TNF-a, i.e. two
cytokines released in the local milieu by other cells
in inflammatory airway disorders3 and effective in
stimulating bronchial epithelial cells.1,23,24 The
activity of salmeterol was tested on two different
epithelial cell functions, i.e. adhesion molecule
(ICAM-1 and VCAM-1) expression and cytokine (IL-8,
GM-CSF and RANTES) release. Among the variety of
surface molecules expressed on the surface of the
bronchial epithelium, ICAM-1 and VCAM-1 were
selected because of their importance in the
interaction between airway epithelial cells and
inflammatory cells.25 Indeed, ICAM-1 is the ligand
for surface molecules expressed on eosinophils,
monocytes and lymphocytes and its expression is
increased at sites of inflammatory reactions and is
associated with leukocyte transmigration, adhesion
and activation.25–27 VCAM-1 acts as ligand for VLA-
4, an adhesion molecule expressed by monocytes,
lymphocytes and eosinophils, and is engaged in
eosinophil activation and survival.25,28,29 The activ-
ity of salmeterol was also tested on the secretion of
three proinflammatory cytokines/chemokines IL-8,
GM-CSF and RANTES. IL-8, recognized as neutrophil
chemoattractant and activator, is also able to
induce T-lymphocyte migration and to enhance
eosinophil locomotion,1,2,30 while GM-CSF is one of
the major ‘‘eosinophilic’’ cytokine being involved
in the maturation, recruitment, activation and
survival of these cells.31 Finally RANTES, a cytokine
active on monocytes and activated memory T cells,
has also been shown to be a potent chemoattrac-
tant for eosinophils and an efficient basophil
histamine-releasing factor.32,33
The results showed that resting or stimulated
airway epithelial cells may express/release adhe-
sion molecules and cytokines at very different
levels and that salmeterol is effective in down-
regulating these biological functions.
Materials and Methods
Isolation and culture of human bronchial
epithelial cells (HBECs)
HBECs were isolated and cultured as previously
described.21 Briefly, human bronchi, obtained from
eight individuals at the time of surgical procedures
for localized lung tumours. The donors were not
treated with inhaled glucocorticosteroids or b2-
adrenoreceptor agonists at the time of surgery. The
bronchi, histologically normal, were trimmed off
the lung parenchyma and peribronchial vascular
structures, and incubated at 41C overnight in
sterile calcium-free Eagle’s MEM (ICN Biomedicals
Inc.) containing 0.1% bacterial protease type XIV
(Sigma-Aldrich, Milan, Italy). Bronchial lumena
were then gently rinsed several times using a
syringe containing MEM plus 10% FCS to detach
the HBECs. The collected cells were washed once in
the same medium, filtered through one layer of
surgical sterile gauze and washed twice with MEM.
The cell count was manually determined using a
standard hemocytomer. Extensive evaluation of
cells prepared with this method showed that
495% of the harvested cells were HBECs (cytocher-
atine positive). HBECs were plated for growth at
371C in 5% CO2 in tissue culture plates (Costar
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Corp., Cambridge, MA, USA) previously coated with
murine type I collagen. LHC basal medium (Biofluids
Inc., Rockville, MD, USA) was used, supplemented
with 5mg/ml insulin, 5mg/ml transferrin, 5mM
phosphoethanolamine/ethanolamine, 10 nM T3,
0.33 nM retinoic acid, trace elements, 0.11mM
calcium, bovine pituitary extract containing
10mg/ml protein (0.5%), 50mg/ml penicillin-strep-
tomycin, and 2mg/ml fungizone.21 The LHC-sup-
plemented medium was mixed 1:1 with RPMI 1640,
a solution found to optimize HBEC growth. In the
average cell preparation, 20–30% of the viable cells
plated at the start of the culture were attached to
the tissue culture plates after 24 hours and about a
quarter of the adherent cells were able to
proliferate. Since the confluent HBECs tend to
assume a squamous shape when replated and are
less responsive to the stimuli, the growing HBECs
were maintained in a subconfluent state by replat-
ing the cells every 2–3 days.
Cells stimulation and evaluation of the
effects of salmeterol on HBEC functions
After being seeded in 24-well tissue plates (70,000
cells well1), previously coated with bovine type I
collagen, HBECs were cultured for 24 h and stimu-
lated with interleukin (IL)-4 (20 ngml1, 1.34 mM,
final concentration,) and/or tumour necrosis factor
(TNF)-a (20 ngml1, 1.18 mM, final concentration)
or, as control, with medium alone.16
Indeed, in preliminary sets of experiments, these
IL-4 and TNF-a concentrations were effective in
inducing an upregulation of the different HBEC
functions tested. To evaluate the activity of the
drug, HBEC cultures were stimulated for 24 h with
IL-4 combined with TNF-a in the presence of
different concentrations of salmeterol (0.1–
100.0 nM). In all the experimental conditions, after
a 24 h incubation, HBECs were trypsinized, washed,
resuspended in the appropriate medium, and
molecule adhesion expression and cytokine release
were evaluated as described below.
Evaluation of adhesion molecule expression
on HBECs
To evaluate the expression of ICAM-1 (CD54) or
VCAM-1 (CD 106), 100 ml of the cell suspensions
were placed into round-bottom microtiter 96-well
plate (Costar Corp), incubated for 30min at 41C
with a monoclonal antibody (mAb) anti-human
(ah)-CD54 (Caltag Laboratories, Burligame, CA) or
ah-CD106 (Southern Biotechnologies Associates,
Inc. Birmingham, USA) fluorescein isothiocyanate
(FITC) conjugated (Caltag Laboratories, Burligame,
CA), washed twice and then fixed with 0.5%
paraformaldehyde.16 The cells were analyzed by
single color immunofluorescence flow cytometry
(Becton Dickinson Immunocytometry Systems;
Mountain View, CA, USA). To compare the fluores-
cence intensities of different samples from the
same experiments, the analysis were performed
with identical settings of the logarithmic amplifier
and listmode files were analysed with CELLQuest
software (Becton Dickinson). After conversion to
linear fluorescence intensity units to obtain a linear
function of fluorescence intensity over a wide
range, the average background linear fluorescence
obtained with the control antibody, the anti-human
(ah)-CD3 FITC, was subtracted from the average
fluorescence intensity of the specifically stained
cells. The possible, changes in cell size were
controlled by means of the forward light scatter
signal of the flow cytometer, proportional to cell
size and algebraically adjusting for increases in cell
surface area so that the intensity in relative
linear fluorescence units could be obtained.16 This
correction permits to directly correlate the aver-
age fluorescence intensity with the cell surface
density of the stained antigens. All experiments
were performed in triplicate. The intensity of
fluorescence was expressed as mean fluorescence
channel (mfc).16
Evaluation of cytokine release by HBECs
Culture supernatants from HBEC cultures were
tested for the presence of IL-8, GM-CSF, and
RANTES. Concentrations of RANTES in the cell
supernatants were determined by enzyme-linked
immunosorbent assay (ELISA) (Amersham Interna-
tional) according to manufacture’s instructions,
while IL-8 and GM-CSF were measured by a
sensitive, novel cytometric technique, Quanti Flow
TM IFA System, (BioErgonomics, Inc., White Bear
Lake, MN).22 Briefly, for the last system, the
samples were incubated with cytokine capture
beads for 1 h at room temperature with mixing
(nutation). After washing, the samples were in-
cubated with a fluorescein-labelled reporter anti-
body (10 mL) for 30min at room temperature with
nutation. After washing, the samples were resus-
pended in PBS and analyzed by flow cytometry.
Concentration of secreted cytokine was deter-
mined by comparing mean fluorescence channel
of the sample to standard curve. The standard
curve was developed by plotting the mean fluores-
cence channel of each standard vs. the concentra-
tion of the cytokine on a log vs. log graph.22
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Statistical analysis
Statistical evaluation was performed on a Power
Macintosh G3 (Apple Computer, Cupertino, CA,
USA) using the statistical software package Stat-
view II (Brainpower Inc., Calabasas, CA, USA). All
data are expressed as arithmetic mean7standard
error of the mean. Paired t-test, unpaired t-test or
Mann–Whitney U-test was used when appropriate.
The mean values were considered to be statistically
significant when the probability of the event was
below 5% (Po0.05).
Results
Characteristics of human bronchial epithelial
cell (HBEC) cultures
Number, differential count and viability of the cell
collected by scraping surgically resected bronchi
were evaluated. The total number of HBECs
recovered was 18.272.2 106 cells. The percen-
tage of cells identified as HBECs on cytocen-
trifuge preparations were 99.470.3%; only a small
proportion of macrophages (0.370.2%), lympho-
cytes (0.270.1%), polymorphonuclear leukocytes
(0.370.3%) contaminated the samples collected
(not shown). Finally, the proportion of viable
HBECs, i.e. excluding trypan blue dye, was con-
sistently elevated in the different experiments
(87.277.6%).
Constitutive and IL-4 and/or TNF-a-induced
adhesion molecule expression and cytokine
release
Evaluating adhesion molecule expression on unsti-
mulated HBECs growing in LHC9 medium, we found
that the constitutive expression of ICAM-1 was
higher than that of VCAM-1 (Po0.05) (Fig. 1A).
Stimulation of the cells with IL-4 or TNF-a or with
the combination of IL-4 plus TNF-a, induced an
increase in ICAM-1 expression (Po0.05, each
comparison with unstimulated cells) (Fig. 1B). In
contrast, only the combination of IL-4 plus TNF-a
enhanced VCAM-1 expression (Po0.01, each com-
parison) (Fig. 1C).
HBECs constitutively secreted detectable
amounts of IL-8, GM-CSF and RANTES. However,
the IL-8 levels in the supernatants were over 200-
fold higher than those of GM-CSF and over 3500-
fold higher than those of RANTES (Po0.001, each
comparison) (Fig. 2A–C). While incubation with IL-4
or TNF-a alone induced a significant increase in the
release of IL-8 and GM-CSF (Po0.05, each compar-
ison with unstimulated cells), RANTES secretion
was increased only in cultures stimulated by IL-4
(Po0.05, comparison with unstimulated cells).
Interestingly, the combination of IL-4 plus TNF-a
induced a statistically significant increase in the
release of RANTES and GM-CSF, as compared to IL-4
or TNF-a alone, and in the release of IL-8, as
compared TNF-a alone (Fig. 2A–C). The magnitude
of the increase in IL-8, GM-CSF and RANTES
production by stimulated epithelial cells was not
related to the constitutive levels of the same
cytokines (P40.05, each correlation, not shown).
Effects of salmeterol on IL-4þTNF-a-induced
HBEC adhesion molecule expression and
cytokine release
Since neither IL-4 nor TNF-a alone significantly
modified VCAM-1 expression, the effects of salme-
terol on adhesion molecule expression and cytokine
release were evaluated on HBECs stimulated by IL-4
plus TNF-a.
Independently from the constitutive or the
induced levels of adhesion molecule expression,
the addition of salmeterol to the culture medium
induced a dose-dependent inhibition of the expres-
sion of ICAM-1 and VCAM-1 (Fig. 3) induced by
IL-4þTNF-a, being significant (as compared to
untreated cells) at the two highest concentrations
tested (Po0.05, each comparison). Similar results
was obtained when cytokine release were evalu-
ated. Salmeterol was effective in downregulating
IL-8, GM-CSF and RANTES release (Fig. 4) in a dose-
dependent fashion, the inhibition being significant
(as compared to untreated cells) at the two highest
concentrations tested (Po0.05, each comparison).
The degree of inhibition was similar for ICAM-1
and VCAM-1 expression (P40.05; each compari-
sons) but higher for RANTES, as compared to IL-8,
GM-CSF (Po0.05; each comparison).
Discussion
Working on cells, freshly isolated from surgically
resected bronchi, we have shown that: (a) bron-
chial epithelial cells can express, constitutively and
upon activation, adhesion molecules, such as ICAM-
1 and VCAM-1, and secrete proinflammatory pro-
teins, such as IL-8, GM-CSF and RANTES; (b)
salmeterol, a long acting b2-adrenergic drug, is
effective in vitro in inhibiting adhesion molecule
expression and chemokine/cytokine release by
stimulated epithelial cells.
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In the experimental conditions here reported,
ICAM-1 and VCAM-1 expression and IL-8, GM-CSF
and RANTES release by stimulated airway epithelial
cells were significantly downregulated by salme-
terol. However, while the degree of inhibition
observed was similar for the two types of adhesion
molecules, a significantly higher downregulation of
RANTES release, as compared to IL-8 or GM-CSF
release was observed.
Salmeterol, like the other b2-adrenoreceptor
agonists acts through the interaction with specific
seven-transmembrane receptors located in the
plasma membranes of a variety of cells, including
smooth muscle cells, blood mononuclear cells,
fibroblasts and epithelial cells.5–7 Although some
of the response to b2-agonists may be mediated
through cAMP-independent mechanisms34 classi-
cally the occupation of a b2-adrenoreceptor by an
agonist results in a conformational change that
leads to G protein activation and conversion of ATP
to cAMP, the second messager of b2-adrenoreceptor
function.35 In the airways, cAMP induces smooth
muscle relaxation through the activation of the
enzyme protein kinase A (PKA) which, besides
phosphorilating regulatory proteins involved in the
control of muscle tone, lowers the cellular calcium
ion (Ca2þ ) concentration.35 Although PKA may also
interfere with the transcription of genes related to
synthesis and release of a variety of proteins, in-
cluding proinflammatory cytokines, the mechanisms
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Figure 1 Constitutive and cytokine-induced-adhesion molecule ICAM-1 and VCAM-1 expression by human bronchial
epithelial cells. (A) Flow cytometric histograms of constitutive ICAM-1 and VCAM- 1 expression by unstimulated HBECs.
Cell number is shown on the ordinate, while the green fluorescence intensity given by anti-human ICAM-1 or anti-human
VCAM-1 FITC-conjugated monoclonal antibqdy is shown on the abscissa as mean fluorescence channel (mfc). (B and C)
Changes of ICAM-1 expression (B) or VCAM-1 expression (C) on the surface of HBECs induced by IL-4 (20 ng-ml1), TNF-a
(20 ng-ml1), or IL-4þ TNF-a (20 ngml1). The intensity of adhesion molecule expression (mean fluorescence channel
(mfc)) is shown on the ordinate, whereas the different culture conditions are shown on the abscissa. The data are
expressed as mean7SEM, and represent the results of eight experiments *Po0.05; **Po0.01; as compared to
unstimulated cell cultures.
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Figure 2 Changes of IL-8 (A), GM-CSF (B) and RANTES (C) release by human bronchial epithelial cells induced by IL-4,
TNF-a or IL-4þ TNF-a. The cytokine concentrations, expressed as pgml1 are shown on the ordinate, whereas the
different culture conditions, CTR, IL-4 (20 ngml1), TNF-a (20 ngml1) and IL-4þ TNF-a (20 ngml1) are shown on the
abscissa. The data are expressed as mean7SEM, and represent the results of eight experiments *Po0.05; **Po0.01; as
compared to unstimulated cell cultures.
Figure 3 Effects of different concentrations of salme-
terol on the IL4þTNF-a-induced ICAM-1 (’) and VCAM-1
(&) expression on human bronchial epithelial cells. The
salmeterol induced-inhibition of ICAM-1 and VCAM-1
expression is shown on the ordinate as percentage
whereas the different concentrations (0.1 to 100 nM) of
the drug are reported on the abscissa. The data are
expressed as mean7standard error of the mean, and
represent the results of eight experiments *Po0.05, as
compared to control cell cultures grown in the absence of
the drugs.
Figure 4 Effects of different concentrations of salme-
terol on the IL4þTNF-a-induced IL-8 ( ), GM-CSF (&)
and RANTES (’) release by human bronchial epithelial
cells. The salmeterol induced-inhibition of IL-8, GM-CSF
and RANTES release is shown on the ordinate as
percentage whereas the different concentrations
(0.1–100 nM) of the drug are reported on the abscissa.
The data are expressed as mean7standard error of the
mean, and represent the results of eight experiments
Po0.05, as compared to control cell cultures grown in
the absence of drugs.
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regulating non-muscle relaxant cell functions are
not fully understood. There is however convincing
evidence that, at least for inflammatory and
immunoeffector cells, b2-adrenoreceptor-induced
inhibition of cytokine release is strictly related to
the increase in intracellular cAMP levels.10,36 As
demonstrated in the present paper for airway
epithelial cells, huge differences in the degree of
b2-adrenoreceptor-induced inhibition on cytokine
release by mononuclear cells were detected when
various interleukins were compared. Indeed, for
unknown reasons IL-12 production by monocytes
and dendritic cells is effectively inhibited by
b2-agonists, while in the same experimental system
IL-lb, IL-lb and IL-6 are unaffected.36 Differences
between cells at various stages in development or
different cell types have been also demonstrated.
For example, while peripheral blood monocytes
exhibit an inhibition of lipopolysaccharide-induced
IL-8 gene transcription and protein secretion when
treated with cAMP-elevating autacoid PGE2, no
effects are seen in alveolar macrophages.37 Simi-
larly, discrepancies are also found when b2-adre-
noreceptor agonist-mediated downregulation of
surface molecule expression by different cell types
are compared. Indeed, while salmeterol and
fenoterol were effective in downregulating adhe-
sion molecules on monocytes, airway epithelial
cells and fibroblasts9,16,38 no inhibition of the PAF-
induced CD11 upregulation on eosinophils when the
cells were incubated with procaterol was ob-
served.39 The data here reported, on a significant
‘‘downregulating’’ activity of salmeterol on airway
epithelial cell functions are partially in disagree-
ment with the results of previous studies. Indeed,
while fenoterol, a short-acting b2-adrenoreceptor
agonists, effectively inhibited ICAM-1 expression on
airway epithelial cells,16 contrasting results were
demonstrated on IL-8, RANTES and GM-CSF release
when bronchial epithelium was exposed to other
two short-acting b2-adrenoreceptor agonists, sal-
butamol and procaterol.17,18 More recently, in a
‘‘similar’’ in vitro systems, looking at TNF-a–
stimulated bronchial epithelial cells, was observed
an inhibitory effect of formoterol on GM-CSF
release, at levels comparable to those described
here with salmeterol, which however was asso-
ciated with an enhancement of IL-8 release.19
These conflicting results may be related to a
variety of factors that include differences in
experimental protocols, b2-adrenoceptor poly-
morphism genotype of the donors40, characteristics
of the compound tested and the stimulus used to
activate the cells. In addition, although in the same
subject, b2-adrenoceptors appear to be similar in
the cells of different tissues,41 cellular responses
are dependent on cell types and may also vary
between asynchronous cells, at different stages of
the cell cycle.42
In conclusion, the present report indicates that
salmeterol, at concentrations similar to those
reached at the airway levels using the drug by
inhalation9, is effective in downregulating some
pro-inflammatory epithelial cell functions.
A characteristic of many membrane-associated
receptors is desensitization after high dose or
repeated exposure to agonists and b2-adrenorecep-
tors on inflammatory cells appear to become
rapidly uncoupled from their intracellular signalling
pathways and to eventually lost from the cell
surface.1,2 This may be true also for airway
epithelial cells. Indeed, heterogeneity in b-adre-
nergic receptor kinase expression (the enzyme
inducing b2-adrenoceptor phosphorylation, i.e. in-
activation) seems to account for cell-specific
desensitisation of b2-receptor and it has been
shown that the level of b-adrenoceptor kinase
mRNA in airway smooth muscle cells are approxi-
mately 20% of that in bronchial epithelial cells.43,44
Therefore, the in vitro downregulation of proin-
flammatory functions of airway epithelial cells by
salmeterol may not be clinically relevant to the
regular treatment in clinical practice. However, the
result of the present paper, together with other
in vitro data, may possibly explain some acute
clinical ‘‘anti-inflammatory’’ activity of b2-adre-
noreceptor agonists,45,46 not confirmed with the
regular prolonged use of these compounds.47,48
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